Filing Flows › Harmony Biosciences Holdings (HRMY) › Q1 2026
Harmony Biosciences Holdings (HRMY) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Harmony Biosciences Holdings (HRMY) reported revenue of $215M for the first quarter 2026 (Q1 2026), +17% from a year earlier and -12% from the quarter before. Operating margin was 17.3%, net earnings $32.5M (15.1% of revenue).
Harmony Biosciences Holdings, Q1 2026: revenue $215M (+17% year over year), operating margin 17.3%, net earnings $32.5M, operating cash flow $27.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $215M | -12% | +17% |
| Gross profit | $171M | -2% | +12% |
| Operating profit | $37.3M | -3% | -34% |
| Net earnings | $32.5M | +44% | -29% |
| Operating cash flow | $27.8M | -78% | -18% |
What changed
Revenue was $215.4M in Q1 2026, up 17% year over year and down 12% from the previous quarter.
Gross margin was 79.3%, down 3.3 points from Q1 2025. Operating profit was $37.3M, a 17.3% margin (down 13.1 points year over year). Operating profit fell $19.0M even though revenue rose $30.7M versus Q1 2025, so costs grew faster than sales. Operating expenses grew 38% against revenue growth of 17%. The fastest-growing cost line was Research & development (+101%). Net earnings were $32.5M, down 29% year over year. The effective tax rate was 18.1%.
Operating cash flow was $27.8M (down 18% year over year), 85% of net earnings. Non-cash charges added back $6.0M of depreciation and amortization and $10.6M of share-based compensation. Working capital and other items used $21.3M.
Questions
What was Harmony Biosciences Holdings' revenue in the first quarter 2026?
Harmony Biosciences Holdings (HRMY) reported revenue of $215M for the first quarter 2026 (Q1 2026), +17% from a year earlier and -12% from the quarter before.
Was Harmony Biosciences Holdings profitable in the first quarter 2026?
Operating profit was $37.3M (17.3% of revenue) and net earnings $32.5M.